Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Northpond Ventures Information
Geographic Data
Address:
City:
State:
Zip:
Country:
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland. Our mission is to build a better tomorrow. Our investments are focused on life sciences, technology, and affiliated industries.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 4/2021 | VieCure | Series A | 25M |
| 3/2020 | Emulate | Series D | - |
| 3/2021 | Inflammatix | Series D | 0 |
| 5/2019 | IsoPlexis | Series C | 0 |
| 1/2020 | IsoPlexis | Series C | 0 |
| 1/2022 | 64x Bio | Series A | 0 |
| 10/2020 | Ori Biotech | Series A | 0 |
| 3/2022 | Sherlock Biosciences | Series B | 0 |
| 4/2019 | Candel Therapeutics | Series C | 22.5M |
| 4/2021 | Vizgen | Series B | 0 |
| 2/2022 | Scipher Medicine | Series D | 0 |
| 6/2020 | DNAnexus | Series G | 0 |
| 4/2022 | Eleanor Health | Series C | 0 |
| 3/2021 | Scipher Medicine | Series C | 82M |
| 9/2019 | Codex DNA | Series A | 25M |
| 8/2021 | Vigil Neuroscience | Series B | 0 |
| 2/2023 | Garuda Therapeutics | Series B | 0 |
| 8/2019 | SeLux Diagnostics | Series B | 9M |
| 9/2018 | Nanoview Biosciences | Series B | 10M |
| 12/2022 | Sound Agriculture | Series D | 0 |
| 12/2022 | Molecule | Seed Round | 0 |
| 12/2021 | Totus Medicines | Series A | 40M |
| 2/2023 | Faro | Series A | 20M |
| 6/2021 | Faro | Series A | 15M |
| 2/2022 | Walking Fish Therapeutics | Series A | 0 |
| 7/2022 | Delfi Diagnostics | Series B | 0 |
| 4/2019 | Deep Lens | Series A | 0 |
| 4/2019 | Sherlock Biosciences | Series A | 0 |
| 8/2018 | General Automation Lab Technologies | Series A | 10.5M |
| 4/2021 | Outcomes4Me | Series A | 0 |
| 8/2019 | SpeeDx | Series A | 15M |
| 1/2021 | Scitara | Series A | 5M |
| 12/2018 | SeLux Diagnostics | Series B | 25M |
| 8/2020 | Triumvira Immunologics | Series A | 0 |
| 2/2022 | QbDVision | Series A | 0 |
| 1/2020 | Vizgen | Series A | 14M |
| 7/2018 | Farcast | Series C | 40M |
| 10/2021 | Culture Biosciences | Series B | 0 |
| 2/2021 | Syapse | Venture Round | 68M |
| 2/2022 | Story Health | Series A | 0 |
| 12/2020 | Vigil Neuroscience | Series A | 50M |
| 6/2022 | Code Biotherapeutics | Series A | 0 |
| 11/2020 | Refeyn | Series A | 30M |
| 9/2021 | Garuda Therapeutics | Series A | 72M |
| 12/2019 | ChromaCode | Series C | 0 |
| 3/2022 | DNAnexus | Series H | 200M |
| 9/2022 | Elephas | Series B | 41.5M |
| 9/2021 | Elephas | Series A | 20M |
| 3/2022 | OPT Industries | Series A | 15M |
| 7/2022 | Syapse | Growth | 35M |
| 4/2022 | Ansa Biotechnologies | Series A | 68M |
| 3/2021 | StrideBio | Series B | 0 |
| 4/2021 | Current Health | Series B | 43M |
| 1/2021 | Dice Therapeutics | Series C | 80M |
| 6/2021 | CAMP4 Therapeutics | Series A | 0 |
| 2/2021 | Personal Genome Diagnostics | Series C | 0 |
| 1/2022 | Kyverna Therapeutics | Series B | 0 |
| 7/2022 | CAMP4 Therapeutics | Series B | 0 |
| 4/2018 | SeLux Diagnostics | Venture Round | 23.5M |
| 12/2020 | Octave Bioscience | Series B | 32M |
| 4/2022 | OMass Technologies | Series B | 0 |
| 7/2018 | Dice Therapeutics | Series B | 40.5M |
| 12/2019 | Codex DNA | Series A | - |
| 6/2021 | Hawthorne Effect | Series A | 0 |
| 8/2019 | SpeeDx | Series B | - |
| 12/2020 | Nanoview Biosciences | Series B | 6M |
| 4/2019 | 908 Devices | Series E | 17.5M |
| 8/2022 | Vestaron | Series C | 0 |
| 2/2021 | Vestaron | Series B | 0 |
| 10/2018 | Intabio | Series A | 9.5M |
| 6/2022 | Molecule | Seed Round | 0 |
| 2/2023 | Faro Health | Series A | 0 |
| 2/2020 | Intabio | Series B | 18M |
| 10/2018 | Inflammatix | Series B | - |
| 5/2022 | Vestaron | Series C | 0 |
| 10/2021 | SimBioSys | Series A | 0 |
| 9/2021 | Emulate | Series E | 82M |
| 11/2022 | Opna Bio | Series A | 38M |
| 1/2021 | Delfi Diagnostics | Series A | 0 |
| 6/2022 | Transition Bio | Series A | 0 |
| 11/2020 | Artisan Bio | Series A | 21M |
| 2/2022 | 1859 | Series A | 0 |
| 1/2021 | Encodia | Series C | 75M |
| 5/2021 | Torus Biosystems | Series A | 25M |
| 9/2020 | Vigil Neuroscience | Series A | 21M |
| 1/2022 | Scitara | Series B | 15M |
| 5/2019 | Scipher Medicine | Series B | 0 |
| 1/2022 | Ori Biotech | Series B | 0 |
| 12/2019 | General Automation Lab Technologies | Series A | - |
| 12/2020 | General Automation Lab Technologies | Series A | 15M |
| 7/2021 | Slingshot Biosciences | Series A | 0 |
| 6/2019 | Ultivue | Series C | 22M |
| 6/2022 | Vizgen | Series C | 0 |
| 9/2021 | Kytopen | Series A | 0 |
| 5/2021 | Isolere | Seed Round | 7M |
| 2/2019 | Teckro | Series C | 0 |
| 2/2022 | SeLux Diagnostics | Series C | 0 |
| 4/2021 | Ultivue | Series D | 50M |
| 8/2021 | Sound Agriculture | Series C | 0 |
| 11/2021 | Parthenon Therapeutics | Series A | 0 |
| 9/2022 | EnPlusOne Biosciences | Seed Round | 12M |
| 1/2021 | Aro Biotherapeutics | Series A | 88M |
| 2/2020 | SpeeDx | Series B | 15M |
| 8/2021 | Dice Therapeutics | Series C | 60M |
| 1/2020 | Inflammatix | Series C | 0 |
| 3/2022 | Triumvira Immunologics | Series A | 0 |
| 7/2022 | Syapse | Venture Round | 0 |
| 7/2022 | CAMP4 Therapeutics | Series B | 0 |
| 7/2022 | Delfi Diagnostics | Series B | 0 |
| 6/2022 | Molecule | Seed Round | 0 |
| 6/2022 | Code Biotherapeutics | Series A | 0 |
| 6/2022 | Vizgen | Series C | 0 |
| 6/2022 | Transition Bio | Series A | 0 |
| 4/2022 | OMass Technologies | Series B | 0 |
| 4/2022 | Ansa Biotechnologies | Series A | 0 |
| 4/2022 | Eleanor Health | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
